Patent · US Expired

Colon tumor specific binding peptides

US7452965B2 · kind B2 · utility

3Cited by
3References
14Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 7, 2003
Grant dateNov 18, 2008
Priority date—
Expiry dateApr 24, 2023

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2500/10
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Phage display was used to screen peptide libraries that distinguish between well-differentiated (HCT116) and poorly-differentiated colon carcinoma cells (HT29). The screening protocol used selection and subtraction on intact, viable cells, resulting in phage libraries exhibiting high binding selectivity for the poorly-differentiated HT29 cells. A nine amino acid, disulfide-constrained peptide (RPM) was identified that selectively bound and was internalized into colon cancer cells. The peptide may be used to detect colon cancer cells and also may be used to selectively deliver therapeutic agents to the cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.